Clinical Trial

A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer

Withdrawn Phase 1/2
View on ClinicalTrials.gov →
Why the trial stopped
0 participants enrolled
Summary
To apply its findings as rationale needed for a subsequent registration trial towards a novel indication for systemic treatment of resectable, lung-limited metastatic CRC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-15; most recent amendment 2026-03-10.
Status change: Not Yet Recruiting → Withdrawn 2026-01-27
Trial Details
NCT Number NCT07137390
Lead Sponsor M.D. Anderson Cancer Center
Conditions Colorectal Cancer
Start Date 2025-09-03
Primary Completion 2026-01-22 (estimated)
Study Completion 2026-01-22 (estimated)
Updated on ClinicalTrials.gov 2026-03-11